Baush

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Bausch + Lomb and Technolas Perfect Vision’s Victus Femtosecond Laser platform for use during cataract and corneal surgical procedures.

The CE-marked Victus platform is designed to create a corneal flap in patients undergoing LASIK surgery or other treatment requiring initial lamellar resection of the cornea and anterior capsulotomy during cataract surgery.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Early published data suggest that laser refractive cataract surgery, as provided by the Victus platform, may allow physicians to create a controllable and centered capsulotomy, according to the company.

Technolas Perfect Vision (TPV) chief executive officer Kristian Hohla said the use of Victus platform helps ophthalmic surgeons to potentially enhance patient outcomes.

“We look forward to the continued commercialisation of the technology around the world, so that ophthalmic surgeons can experience its potential for themselves,” Hohla added.

Bausch + Lomb global surgical business executive vice president and president John Barr said the company’s research and development partnership with TPV has allowed it to provide a broader suite of ophthalmic surgical products and expand the global reach of the new technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Since signing a definitive agreement with an option to purchase TPV last September, the two organisations have made substantial technical and commercial progress in the field of advanced refractive and cataract technologies,” Barr added.

“This FDA clearance further strengthens our relationship with TPV and we look forward to bringing the power of the Victus femtosecond laser to the U.S.”

With plans to introduce the Victus platform at surgery centres in the US, both companies are working together to gain approval for additional US applications to maximise use of all of the capabilities of the Victus laser in cataract and refractive procedures.

Image: Bausch + Lomb’s headquarters in Rochester, New York, US. Photo: DanielPenfield.